Interim results of a Phase 2b/3 trial investigating a long-acting injectable of cabotegravir for pre-exposure prophylaxis of HIV

4 Aug 2020

Kirsty LEE

This content is sponsored. It is intended for healthcare professionals only.

Pre-exposure prophylaxis (PrEP) is a human immunodeficiency virus (HIV) prevention option that has until recently, consisted of taking a daily oral combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF). The strongest determinant of PrEP effectiveness is adherence. Issues exist in ensuring PrEP access for marginalized populations such as Black and minority ethnic groups, and transgender women (TGW). These populations have also been underrepresented in clinical trials.

interim-results-of-a-Phase-2b-3-trial-investigating-a-long-acting-injectable-of-cabotegravir-for-pre-exposure-prophylaxis-of-HIV

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.

Interim results of a Phase 2b/3 trial investigating a long-acting injectable of cabotegravir for pre-exposure prophylaxis of HIV

Related posts